Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENDER
NCT05620901Phase 1Completed
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexamethasone in ocular inflammation (2 arms). Primary endpoint: Pain as Measured by the FLACC Pain Scale at Day 45. Started Feb 2023; status: completed.
02
Drugs
dexamethasone
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT05620901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620901.